# Reirradiation and Niraparib in Patients With Recurrent Glioblastoma

> **NCT05666349** · PHASE1 · WITHDRAWN · sponsor: **University College, London**

## Conditions studied

- Recurrent Glioblastoma

## Interventions

- **DRUG:** Niraparib
- **RADIATION:** Re-irradiation (re-RT)

## Key facts

- **NCT ID:** NCT05666349
- **Lead sponsor:** University College, London
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2023-10-13
- **Primary completion:** 2023-10-13
- **Final completion:** 2023-10-13
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Funder support withdrawn 13-Oct-2023. Study did not open to recruitment.
- **Last updated:** 2024-03-26

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05666349

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05666349, "Reirradiation and Niraparib in Patients With Recurrent Glioblastoma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05666349. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*